Top Stories
Partner Therapeutics Wins First FDA Approval for Ultra-Rare NRG1 Fusion Cholangiocarcinoma
According to MedCity News, Partner Therapeutics received FDA approval on May 8, 2026 for Bizengri (zenocutuzumab-zbco) to treat adults with advanced cholangiocarcinoma harboring NRG1 gene fusions who have progressed after prior systemic therapy. The approval was granted under the FDA Commissioner's National Priority Voucher pilot program, an expedited pathway, and is based on a single-arm trial — meaning continued approval may be contingent on confirmatory data. Pharmaceutical Technology reported this marks the first FDA-approved treatment specifically for this ultra-rare mutation subset, affecting roughly 0.2% of all cholangiocarcinoma patients. The approval creates a new treatment paradigm for bile duct cancer, historically one of oncology's most challenging malignancies with limited therapeutic options. Bizengri is a bispecific antibody targeting the HER2 and HER3 receptors activated by NRG1 fusion proteins, representing a precision oncology approach to an orphan indication. The drug demonstrated a 36.8% overall response rate in 19 evaluable patients in the eNRGy trial, per the FDA approval announcement. Partner Therapeutics establishes first-to-market position in NRG1 fusion cholangiocarcinoma
Daiichi Sankyo Maps ADC Dominance Into Top-5 Global Oncology Ambitions by 2035
Fierce Biotech reported that Daiichi Sankyo unveiled a five-year business plan targeting global top-5 oncology ranking by 2035, leveraging its antibody-drug conjugate leadership position. The Japanese pharma will invest $1.3 billion in efficiency initiatives while expanding beyond its current ADC franchise of Enhertu, Dato-DXd, and other pipeline assets. According to the plan, Daiichi aims to transform from a regional player into a global oncology powerhouse, capitalizing on an ADC market that industry forecasts (cited by Fierce Biotech) project could reach approximately $35 billion by 2030. The strategy positions Daiichi to compete directly with established leaders like Roche, Bristol Myers Squibb, and Merck in the global oncology hierarchy. Daiichi currently holds three approved ADCs (including Enhertu and Datroway, both co-marketed with AstraZeneca), while Pfizer leads on breadth with five approved ADCs following its Seagen acquisition, per Fierce Biotech. Daiichi Sankyo leverages ADC first-mover advantage into comprehensive oncology expansion strategy
Bristol Myers Squibb and Hengrui Forge $15.2B Alliance for Early-Stage Drug Development
Pharmaceutical Technology reported that Bristol Myers Squibb and Hengrui announced on May 12, 2026 a strategic collaboration with potential total value of up to $15.2 billion, covering 13 early-stage programs across oncology, hematology, and immunology. The deal structure includes four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five innovative assets to be jointly discovered and developed. BMS will pay Hengrui up to $950 million in upfront and anniversary payments (including a $600 million upfront), with the remainder tied to development, regulatory, and commercial milestones. The transaction is expected to close in Q3 2026, pending Hart-Scott-Rodino antitrust review. The partnership reflects the growing importance of China-US drug development bridges, as Western pharma seeks access to Chinese innovation while Chinese companies pursue global market entry. Both Bristol Myers Squibb and Hengrui gain strategic market access through bilateral asset exchange
Pipeline Watch
According to Targeted Oncology, the FDA awarded breakthrough therapy designation to emiltatug ledadotin for treating adenoid cystic carcinoma, a rare head and neck malignancy. The designation accelerates development timelines for this antibody-drug conjugate targeting a historically difficult-to-treat cancer subset with limited therapeutic options.
CancerNetwork published progression-free survival and overall survival results from the Phase 3 MONALEESA-3 trial, focusing on postmenopausal patients with HR-positive, HER2-negative advanced breast cancer and invasive lobular carcinoma subtype. The analysis examined ribociclib plus fulvestrant efficacy in this specific breast cancer histology, providing granular efficacy data for treatment decision-making.
ClinicalTrials.gov listed a new randomized controlled trial evaluating pressurized intraperitoneal aerosol chemotherapy (PIPAC) feasibility and preliminary efficacy in advanced epithelial ovarian cancer. The recruiting study represents novel drug delivery approaches for peritoneal malignancies, potentially improving chemotherapy distribution and reducing systemic toxicity in ovarian cancer patients.
Competitive Landscape
Daiichi Sankyo positions itself as an ADC franchise leader with Enhertu, Datroway and additional approved assets (several co-developed/co-marketed with AstraZeneca), according to Fierce Biotech. Pfizer holds the broadest approved ADC portfolio post-Seagen acquisition, while Roche maintains long-standing positions with Kadcyla and Polivy. Daiichi Sankyo aims to convert ADC strength into top-5 global oncology ranking by 2035
| Company | Approved ADCs (illustrative) | ADC Pipeline Depth |
|---|---|---|
| Pfizer (post-Seagen) | 5 (Adcetris, Padcev, Tivdak, Mylotarg, Besponsa) | ~12 in development |
| Daiichi Sankyo | 3 (incl. Enhertu, Datroway — co-marketed with AZ) | Multiple Phase 3 |
| Roche | 2 (Kadcyla, Polivy) | Phase 2/3 |
| AstraZeneca | 2 (Enhertu, Datroway — with Daiichi) | Phase 2/3 |
Per MedCity News and Pharmaceutical Technology, Partner Therapeutics secured first-mover advantage in NRG1 fusion cholangiocarcinoma with zero competitors in the 0.2% patient subset, establishing pricing power in ultra-orphan oncology.
The Bristol Myers Squibb-Hengrui $15.2 billion alliance exemplifies growing trend of bilateral asset exchanges, per Pharmaceutical Technology, as Western and Chinese companies seek mutual market access through strategic partnerships rather than traditional licensing.
Forward Looking
- Partner Therapeutics' Bizengri launch metrics will establish pricing benchmarks for ultra-rare oncology indications, with NRG1 fusion-positive cholangiocarcinoma estimated to affect only a few hundred patients annually worldwide.
- Daiichi Sankyo's 2035 strategy execution will determine whether ADC leadership translates into comprehensive oncology market share gains against established competitors.
- Bristol Myers Squibb-Hengrui collaboration asset progression through clinical trials will validate $15.2 billion partnership valuation over next 18-24 months.
- FDA breakthrough therapy designation for emiltatug ledadotin positions adenoid cystic carcinoma as next rare cancer market for ADC competition expansion.
🔓 Oncology Intelligence Digest • April 24, 2026
Oncology Intelligence Digest April 24, 2026 Biogen struck an $850M deal for felzartamab in Greater China to challenge
View Archive🔓 Oncology Intelligence Digest • March 24, 2026
Oncology Intelligence Digest March 24, 2026 Bristol Myers Squibb locked in dual US and EU approvals for Opdivo
View Archive🔓 Oncology Intelligence Digest • March 13, 2026
Oncology Intelligence Digest March 13, 2026 Immutep abandoned its Phase 3 LAG-3 checkpoint inhibitor trial in first-line NSCLC
View Archive🔓 Oncology Intelligence Digest • April 17, 2026
Oncology Intelligence Digest April 17, 2026 Revolution Medicines' daraxonrasib pancreatic cancer breakthrough drives reported buyout talks past $30
View Archive🔓 Oncology Intelligence Digest • March 31, 2026
Oncology Intelligence Digest March 31, 2026 The EMA's CHMP recommended EU approval of Amgen's Imdelltra (tarlatamab) for extensive-stage
View Archive🔓 Oncology Intelligence Digest • April 7, 2026
Oncology Intelligence Digest April 07, 2026 Gilead Sciences acquired German ADC specialist Tubulis for $3.1 billion upfront plus
View Archive🔓 Oncology Intelligence Digest • March 20, 2026
Oncology Intelligence Digest March 20, 2026 Novartis fires the biggest BD shot of 2026 so far with a
View Archive🔒 Oncology Intelligence Digest • May 12 2026
Oncology Intelligence Digest May 12, 2026 Partner Therapeutics secured FDA approval for Bizengri, marking the first approved therapy
Unlock Now🔓 Oncology Intelligence Digest • April 10, 2026
Oncology Intelligence Digest April 10, 2026 Gilead Sciences announced a trio of oncology acquisitions spanning CAR-T, T-cell engagers,
View Archive🔓 Oncology Intelligence Digest • May 1, 2026
Oncology Intelligence Digest May 01, 2026 The FDA approved Veppanu (vepdegestrant), the first-ever PROTAC therapy, on May 1,
View Archive🔓 Oncology Intelligence Digest • May 8, 2026
Oncology Intelligence Digest May 08, 2026 Gilead scored a major victory in first-line triple-negative breast cancer with two
View Archive🔓 Oncology Intelligence Digest • March 17, 2026
Oncology Intelligence Digest March 17, 2026 The FDA approved two major frontline therapies: AstraZeneca's acalabrutinib plus venetoclax for
View Archive🔓 Oncology Intelligence Digest • April 3, 2026
Oncology Intelligence Digest April 03, 2026 The sidelining of the U.S. Preventive Services Task Force by HHS Secretary
View Archive🔓 Oncology Intelligence Digest • April 21, 2026
Oncology Intelligence Digest April 21, 2026 Lilly deepens its in vivo CAR-T bet with a $3.25 billion upfront
View Archive🔓 Oncology Intelligence Digest • March 10, 2026
Oncology Intelligence Digest March 10, 2026 Bristol Myers Squibb posted its first phase 3 win for mezigdomide in
View Archive🔓 Oncology Intelligence Digest • April 28, 2026
Oncology Intelligence Digest April 28, 2026 AbbVie committed up to $1.45 billion to enter the pan-RAS inhibitor space
View Archive🔓 Oncology Intelligence Digest • April 14, 2026
Oncology Intelligence Digest April 14, 2026 Revolution Medicines delivered unprecedented survival data in pancreatic cancer with its RAS
View Archive🔓 Oncology Intelligence Digest • March 27, 2026
Oncology Intelligence Digest March 27, 2026 Merck fires the biggest oncology deal of March with a $6.7 billion
View Archive🔓 Oncology Intelligence Digest • May 5, 2026
Oncology Intelligence Digest May 05, 2026 Celcuity's Phase 3 VIKTORIA-1 trial achieved its primary PFS endpoint for gedatolisib
View Archive